Jason Broderick

Articles

Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC

June 7th 2021

The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.

Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans

May 19th 2021

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV

February 13th 2021

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC

February 11th 2021

February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC

May 18th 2020

The FDA has approved single-agent atezolizumab as a frontline treatment for patients with advanced non–small cell lung cancer with high PD-L1 expression.

Alvocidib Trial Launches in MDS

May 14th 2020

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China

May 13th 2020

The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

March 12th 2020

The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.

Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial

March 12th 2020

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

Frontline Venetoclax/Obinutuzumab Approved in Europe in CLL

March 12th 2020

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Cirmtuzumab/Ibrutinib Combo Active in Mantle Cell Lymphoma

March 12th 2020

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

Zanubrutinib Highly Active in Non-Hodgkin Lymphoma

December 10th 2017

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

November 10th 2017

The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

FDA Approval Sought for Frontline Cabozantinib in RCC

August 16th 2017

A supplemental new drug application has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Immunotherapy Gains Frontline Foothold in NSCLC

May 29th 2017

Less than 2 years after checkpoint blockade immunotherapy first became available for patients with non-small cell lung cancer, the PD-1 inhibitor pembrolizumab is poised to reshape the treatment paradigm for previously untreated individuals without molecular mutations.

Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

February 3rd 2017

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

ASCO Selects Dramatic Improvement in CLL Care as 'Cancer Advance of the Year'

January 20th 2015

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."